EP2686006B2 - Composition comprising diamine oxidase for the prevention of hangover symptoms - Google Patents

Composition comprising diamine oxidase for the prevention of hangover symptoms Download PDF

Info

Publication number
EP2686006B2
EP2686006B2 EP12711464.3A EP12711464A EP2686006B2 EP 2686006 B2 EP2686006 B2 EP 2686006B2 EP 12711464 A EP12711464 A EP 12711464A EP 2686006 B2 EP2686006 B2 EP 2686006B2
Authority
EP
European Patent Office
Prior art keywords
dao
composition
histamine
caffeine
hangover
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12711464.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2686006B1 (en
EP2686006A1 (en
Inventor
Carlos DUELO RIU
Juan José Duelo Riu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Healthcare Espana SL
Original Assignee
Dr Healthcare Espana SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45922735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2686006(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Healthcare Espana SL filed Critical Dr Healthcare Espana SL
Priority to PL12711464T priority Critical patent/PL2686006T5/pl
Publication of EP2686006A1 publication Critical patent/EP2686006A1/en
Publication of EP2686006B1 publication Critical patent/EP2686006B1/en
Application granted granted Critical
Publication of EP2686006B2 publication Critical patent/EP2686006B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03006—Amine oxidase (copper-containing)(1.4.3.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the present invention refers to a composition comprising diamine oxidase (DAO) and caffeine to block the effects of histamine release caused by consumption of alcoholic drinks and therefore to prevent hangover symptoms.
  • DAO diamine oxidase
  • the effects of alcohol on the organism depend on a series of individual factors and on the environment, as well as on the quantity that has been drunk.
  • the absorption of alcohol, or ethanol occurs when the drink enters the body by the mouth, passes to the oesophagus and reaches the stomach where it is diluted by gastric juices.
  • the speed with which alcohol passes from the stomach to the intestine to mix with the blood flow and to produce its effects is determined by:
  • Alcohol or ethanol is a CNS depressant, an anaesthetic; it is not a stimulant.
  • drinks containing alcohol seem to stimulate because they inhibit the cerebral functions related to learning, judgement and control. This initial disinhibition and euphoria, which can appear after drinking small quantities, have made people believe wrongly that alcoholic drinks are stimulants.
  • Hangover is the result of intoxication of the organism, caused by the ingestion of an excessive dose of alcohol. Hangover is the appearance of a series of symptoms on the day after having drunk alcohol excessively and can become worse if the person smokes excessively.
  • the organism protects itself from intoxication and secretes enzymes that metabolise and excrete the toxins. However, when the ingestion of alcohol is excessive the capacity of the organism to metabolise it is less and the symptoms of hangover appear.
  • hangover is due to the metabolic processes of the liver, the diuretic effects of alcohol and the reduction in blood sugar.
  • glycogen a substance that is responsible for storing sugar in the liver
  • vasopressin is a hormone secreted by the suprarenal gland. This hormone is responsible for maintaining liquid balance in the body, stimulating the kidneys to reabsorb water from the urine. If vasopressin function is inhibited, the kidneys start to eliminate more water than is ingested and causes the organism to seek water from other organs. This causes the meninges (membranes covering the brain) to lose water and therefore produces a headache.
  • Headache common in all people suffering from hangover, results from dilation of the blood vessels due to the effect of some vasodilator substances (such as histamine) in the organism.
  • vasodilator substances such as histamine
  • Histamine [2-(4-imidazolyl)ethylamine] is an important mediator of many biological processes including inflammation, secretion of gastric acid, neuromodulation and the regulation of the immune function. Due to its potent pharmacological activity, even at very low concentration, it is necessary to regulate the synthesis, transport, storage, release and degradation of histamine very carefully in order to avoid undesirable reactions. High concentrations of free histamine in the circulation lead to undesirable effects such as headache, blocked nose or rhinorrhoea, obstruction of respiratory pathways, tachycardia, gastric and intestinal pains, eyelid swelling, cutaneous erythema, reduction of arterial pressure, bronchospasms, etc.
  • Histamine is produced by human beings and stored in an inactive form in the metachromatic granules of the mast cells and basophilic leukocytes, where it is available for immediate release. The highest concentrations of histamine are measured in the lungs. After release, histamine is an extraordinary powerful mediator of a large number of physiological and pathophysiological processes, frequently mediated by interaction with the cytokines.
  • Histamine can also enter the human body from the outside as it is generated by microbiological action in the course of processing foods and, consequently, is present in substantial quantities in many fermented foods and drinks such as wine, champagne and a large proportion of alcoholic drinks.
  • the main route of inactivation of ingested histamine is oxidative deamination of the primary amino group, catalysed by diamine oxidase (DAO) to produce imidazole acetaldehyde.
  • DAO diamine oxidase
  • the main function of DAO is to prevent histamine ingested with food from reaching the blood circulation from the intestine.
  • DAO can degrade other biogenic amines such as, for example, putrescine, spermidine and cadaverine. It has a molecular weight of approximately 182 kDa and a carbohydrate ratio of 11 %. It belongs to the copper-containing amine oxidase class that catalyses oxidative deamination of primary amines to give aldehydes, ammonia and hydrogen peroxide. DAO uses molecular oxygen for the oxidative deamination of histamine to imidazole acetaldehyde, ammonia and hydrogen peroxide. Histamine Imidazole acetaldehyde
  • DAO is mainly found in the small intestine, liver, kidneys and blood leukocytes.
  • the level of DAO in the blood of pregnant women is approximately 500 to 1000 times higher than of non-pregnant women, as DAO in pregnant women is additionally formed in the placenta. Histamine is continuously produced in humans and is excreted via the intestine, being degraded on passing through intestinal mucosa by the DAO found there.
  • DAO is a sensitive enzyme that can be inhibited by different substances such as other biogenic amines, alcohol and by its degradation product acetaldehyde, as well as by various medicinal drugs.
  • preventative administration of supplementary amounts of DAO has the effect of degrading excess histamine derived from consumption of alcoholic drinks, compensating for the inhibition of DAO caused by the alcohol consumption.
  • Patent EP 132674 described a procedure for the enzymatic separation of free amines in foods containing high amine content such as chocolate, cheese, especially mature, salami, wine and yeast extracts by the use of amine oxidase enzymes, particularly DAO, obtained from Aspergillus niger, in the presence of molecular oxygen. The presence of these free amines in certain foods is thought to cause migraines.
  • Patent US 4725540 described a procedure for preparing DAO from a microorganism that makes it such as Candida crusei or a bacterium that produces lactic acid in a nutrient medium so that the DAO produced is capable of degrading histamine at a pH of between neutral and approximately 4.
  • Patent application WO 02/43745 from 2001 described the systematic use of DAO of plant origin for the treatment of diseases mediated by histamine, particularly for the treatment of allergies in general and anaphylactic reactions in particular.
  • compositions comprising DAO as the active ingredient, including corresponding dosages and administration protocols.
  • the DAO used originates from plants. No mention has been made of the possible use of DAO compositions for the prevention of the symptoms of hangover.
  • Patent application WO 2006003213 of 2005 referred to pharmaceutical compositions for the treatment of histamine-induced diseases, comprising DAO of animal origin where the composition is presented in a form protected against gastric acid for oral or perioral administration.
  • the compositions are particularly directed for the treatment of urticaria, atopic dermatitis and scombrotoxic poisoning.
  • This patent application favours the use of DAO of non-plant origin because it is argued that this form has the advantage that there are no plant allergens present to have a negative effect on the administration of the DAO, as allergens essentially promote the release of endogenous histamine.
  • the DAO used is preferably obtained from pig kidneys or by recombinant techniques. No mention has been made of the possible use of DAO compositions for the prevention of the symptoms of hangover.
  • DAO is the abbreviation used for the enzyme diamine oxidase responsible for catalysing the oxidative deamination of the primary amine group of histamine to give imidazole acetaldehyde. It is responsible for the main route of histamine inactivation.
  • Non-plant origin means DAO that is not obtained from plants but from animal organisms or from other non-plant organisms. Thus all DAO isolated from living things falls under this definition.
  • Plant origin means all DAO obtained from plant organisms.
  • Biotechnological origin means all recombinant DAO prepared from cell cultures or in non-vegetable organisms of any type where the DNA for DAO has been isolated.
  • Prevention in the context of the present invention is avoiding the appearance of one or more of the symptoms related to hangover.
  • the problem solved by the present invention is that of preventing the undesirable effects of hangover produced as a consequence of the ingestion of alcoholic drinks.
  • the first aspect of the present invention is the composition comprising DAO associated with caffeine for use in the prevention of the symptoms associated with hangover.
  • the second aspect of the present invention is oral compositions comprising DAO containing caffeine, in the form of tablets, capsules and sachets.
  • the third aspect of the present invention is oral compositions comprising DAO prepared from free DAO, in powder, lyophilised powder, microcapsules, nanocapsules or liposomes containing DAO and caffeine.
  • the fourth aspect of the present invention are oral compositions comprising DAO prepared from free DAO, in powder, lyophilised powder, microcapsules, nanocapsules or gastro-protected liposomes containing DAO and also caffeine.
  • the present invention refers to a composition comprising diamine oxidase and caffeine for oral administration for use in the prevention of hangover symptoms produced by the consumption of alcoholic drinks.
  • An embodiment of the first aspect is a composition comprising DAO and caffeine for use in the prevention of the symptoms associated with hangover.
  • the DAO used in the present invention can be either of biotechnological origin or extracted from animals or plants.
  • the DAO used is of non-plant origin, it is preferably in the form of a lyophilised powder. If the DAO used is or plant origin, it may also be in liquid form.
  • compositions comprising DAO and caffeine for use in the prevention of the symptoms associated with hangover, are in the form of tablets, capsules or sachets containing DAO in free form, in powder, lyophilised powder, microcapsules, nanocapsules or liposomes of DAO with gastric protection.
  • compositions comprising DAO also contain caffeine to strengthen the effects of preventing the symptoms associated with hangover.
  • Caffeine is an alkaloid of the xanthine group that has vasoconstriction capacity. Histamine produces vasodilation and this vasodilation produces pain. Caffeine contributes to vasoconstriction and therefore to alleviate the pain.
  • the DAO content in compositions of the present invention is between 0.1 and 50 mg per dose, preferably between 2 and 20 mg.
  • compositions of the present invention is between 1 and 100 mg per dose, preferably between 5 and 50 mg.
  • compositions comprising DAO and caffeine for use in the prevention of the symptoms associated with hangover must be taken between 1 hour and 15 minutes before the start of consuming alcoholic drinks, preferably 1 ⁇ 2 hour before the start of consuming alcoholic drinks.
  • compositions comprising DAO and caffeine of the present invention directly affects the level of histamine in blood and therefore the undesirable effects produced by the ingestion of alcoholic drinks, known as hangover symptoms, but does not influence the level of alcohol in blood.
  • compositions of the present invention are prepared from free DAO, in powder, lyophilised powder, microcapsules, nanocapsules or liposomes of DAO that have an enteric coating layer that protects the DAO from gastric acidity, so that the different forms can be packaged directly in sachets or put into a capsule or compressed to give tablets.
  • the enteric coating layer that coats the different forms rapidly disintegrates or dissolves in a neutral or alkaline medium.
  • the cores can be inert cores based on sugar or similar over which the DAO is applied or these cores can already contain DAO mixed with other excipients.
  • excipients can be binders, surfactants, filling materials, disintegrators, alkaline additives or other pharmaceutically acceptable ingredients either alone or in a mixture.
  • the binders can be a cellulose-like binder such as hydroxypropyl methylcellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose, polyvinylpyrrolidone, sugars, starches and other pharmaceutically acceptable substances with cohesive properties.
  • Suitable surfactants can be from the groups of ionic or non-ionic acceptable surfactants such as, for example, sodium lauryl sulphate.
  • DAO can be mixed with alkaline compounds and additionally mixed with constituents suitable for formulation in a core material.
  • core materials can be produced by extrusion/spheronization or by compression using different processing equipment.
  • DAO can also be mixed with other pharmaceutically acceptable alkaline substances such as salts of phosphoric acid and sodium, potassium, calcium, magnesium and aluminium; carbonic acid, citric acid or other suitably weak organic or inorganic acids; a co-precipitate of aluminium hydroxide/sodium bicarbonate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or compound substances such as Al 2 O 3 .6MgO.CO 2 .12H 2 O, (Mg 6 Al 2 (OH) 16 CO 3 .4H 2 O, MgO.Al 2 O 3 .2SiO 2 .nH 2 O or similar compounds; pH buffering substances such as tris(hydroxymethyl)aminomethane, basic amino acids and their salts or other pharmaceutically acceptable pH buffering substances.
  • alkaline substances such as salts of phosphoric acid and sodium, potassium, calcium, magnesium and aluminium
  • carbonic acid, citric acid or other suitably weak organic or inorganic acids such as aluminiu
  • the enteric coating layers can contain pharmaceutically acceptable plasticizers to obtain the desired mechanical, flexibility and hardness properties.
  • plasticizers can be, for example, triacetin, citric acid esters, phthalic acid esters, cetyl alcohol, polyethylene glycols, polysorbates or other plasticizers.
  • the present invention also refers to a treatment method comprising administration of an oral composition comprising DAO and caffeine, according to any of the embodiments of the present invention, to a patient who presents symptoms of hangover produced by consuming alcoholic drinks or who is at risk from suffering from them, in a therapeutically effective amount.
  • microgranules were coated with hydroxypropyl methylcellulose.
  • the DAO microgranules were compressed with microcrystalline cellulose and sodium stearyl fumarate.
  • microgranules were coated with a methacrylic acid copolymer.
  • the DAO microgranules were compressed with microcrystalline cellulose and magnesium stearate.
  • DAO sachets were prepared containing 100 or 150 mg of DAO microgranules prepared according to the first part of reference example 1.
  • DAO and caffeine sachets were prepared containing 100 or 150 mg of DAO microgranules prepared according to the first part of example 2.
  • DAO capsules were prepared containing 100 or 150 mg of DAO microgranules prepared according to the first part of reference example 1, filling the soft gelatine capsules with the microgranules.
  • DAO and caffeine capsules were prepared containing 100 or 150 mg of DAO microgranules prepared according to the first part of example 2, filling the soft gelatine capsules with the microgranules.
  • Oral compositions containing DAO, either alone or associated with caffeine, the object of the present invention were tested in a total of 52 subjects (40 men and 12 women with ages between 21 and 65 years), as outpatients.
  • histamine levels were analysed before and after taking the trial alcoholic drinks. Normal histamine values for blood were considered to be between 2 and 20 micrograms histamine per decilitre of blood. Elevated histamine values for blood were considered to be over 20 micrograms histamine per decilitre of blood.
  • the consumption of alcoholic drinks that was followed in the protocol of the present trial consisted in taking: 3 glasses of wine, one cognac and two alcoholic drinks (whisky, gin, vodka, rum, or similar).
  • the subjects in the first group were administered compositions of DAO 1 ⁇ 2 hour before starting to consume alcoholic drinks.
  • the subjects in the second group did not take DAO compositions before starting to consume alcoholic drinks.
  • Table 1 Comparative results of the symptoms of hangover between subjects taking DAO tablets, of Reference Example 1, and those not taking DAO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
EP12711464.3A 2011-03-18 2012-03-16 Composition comprising diamine oxidase for the prevention of hangover symptoms Active EP2686006B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL12711464T PL2686006T5 (pl) 2011-03-18 2012-03-16 Kompozycja zawierająca oksydazę diaminową do zapobiegania objawom kaca

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201130380A ES2388515B1 (es) 2011-03-18 2011-03-18 Uso de la diaminooxidasa para la prevención de los síntomas de la resaca.
PCT/IB2012/051275 WO2012127391A1 (en) 2011-03-18 2012-03-16 Composition comprising diamine oxidase for the prevention of hangover symptoms

Publications (3)

Publication Number Publication Date
EP2686006A1 EP2686006A1 (en) 2014-01-22
EP2686006B1 EP2686006B1 (en) 2016-12-14
EP2686006B2 true EP2686006B2 (en) 2020-02-19

Family

ID=45922735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12711464.3A Active EP2686006B2 (en) 2011-03-18 2012-03-16 Composition comprising diamine oxidase for the prevention of hangover symptoms

Country Status (13)

Country Link
US (1) US20130344136A1 (es)
EP (1) EP2686006B2 (es)
CN (1) CN103429257A (es)
BR (1) BR112013023710A2 (es)
CO (1) CO6801745A2 (es)
DK (1) DK2686006T4 (es)
ES (2) ES2388515B1 (es)
HU (1) HUE033445T2 (es)
MX (1) MX346159B (es)
PL (1) PL2686006T5 (es)
PT (1) PT2686006T (es)
RU (1) RU2627128C2 (es)
WO (1) WO2012127391A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426539B1 (es) 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
EP2956269B1 (en) 2013-02-15 2021-10-13 Matthew Fagan Method and system of processing of a long product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703045A (en) † 1983-09-24 1987-10-27 Societe De Conseils De Recherches Et D'applications Scientifiques Therapeutic compositions for the treatment of hangover
WO2006003213A1 (de) † 2004-07-07 2006-01-12 Albert Missbichler Pharmazeutische zusammensetzungen, die diaminooxidase enthalten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319540D0 (en) 1983-07-20 1983-08-24 Bovril Ltd Amine removal
US4725540A (en) 1984-07-09 1988-02-16 Emil Underberg Process for the preparation of amine-oxidase containing material, so produced amine-oxidase containing material
DE19502789A1 (de) 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
RU2143211C1 (ru) * 1999-04-08 1999-12-27 Общество с ограниченной ответственностью "Производственно-торговое предприятие "Медтехника" Биологически активная пищевая добавка для алкогольных напитков
IT1317067B1 (it) * 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US7063865B2 (en) * 2002-05-10 2006-06-20 Jeremy Park Jones Composition and method for substantially reducing the deleterious effects of alcohol on the body
KR101442047B1 (ko) * 2005-09-22 2014-09-18 유키지루시 메그밀크 가부시키가이샤 스핑고미엘린 함유 의약, 음식품 또는 사료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703045A (en) † 1983-09-24 1987-10-27 Societe De Conseils De Recherches Et D'applications Scientifiques Therapeutic compositions for the treatment of hangover
WO2006003213A1 (de) † 2004-07-07 2006-01-12 Albert Missbichler Pharmazeutische zusammensetzungen, die diaminooxidase enthalten

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUNELLO WÜTHRICH: "Nigrane-Attacken, Tropfnase, Bauchgrimmen", WEIN GOERMET, 2007, pages 119 - 120 †
DAOSIN †
HAEBERLE M: "Supplementation of diamine-oxidas - a new approach in the treatment of histamine intolerance", ACTA DERMATO-VENEREOLOGICA, vol. 87, no. 5, 1 September 2007 (2007-09-01), pages 459 - 480, XP055418118 †
SWIFT, R: "Alcohol hangover", ALCOHOL HEALTH & RESEARCH WORLD, vol. 22, no. 1, 1998, pages 54 - 60 †

Also Published As

Publication number Publication date
CN103429257A (zh) 2013-12-04
MX346159B (es) 2017-03-09
ES2388515A1 (es) 2012-10-16
DK2686006T4 (da) 2020-05-18
PL2686006T3 (pl) 2017-07-31
CO6801745A2 (es) 2013-11-29
ES2618930T5 (es) 2020-11-04
RU2013144967A (ru) 2015-04-27
EP2686006B1 (en) 2016-12-14
WO2012127391A1 (en) 2012-09-27
DK2686006T3 (en) 2017-03-13
PT2686006T (pt) 2017-03-20
EP2686006A1 (en) 2014-01-22
MX2013010694A (es) 2013-10-03
ES2388515B1 (es) 2013-10-01
ES2618930T3 (es) 2017-06-22
RU2627128C2 (ru) 2017-08-03
HUE033445T2 (en) 2017-11-28
PL2686006T5 (pl) 2020-07-13
US20130344136A1 (en) 2013-12-26
BR112013023710A2 (pt) 2016-12-13

Similar Documents

Publication Publication Date Title
Wöhrl et al. Histamine intolerance-like symptoms in healthy volunteers after oral provocation with liquid histamine.
EP2315582B1 (en) Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20100247489A1 (en) Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems
US9364437B2 (en) Diaminooxidase-containing pharmaceutical compositions
EP2686006B2 (en) Composition comprising diamine oxidase for the prevention of hangover symptoms
US20230165920A1 (en) Composition for increasing sexual desire or pleasure
JP2002265365A (ja) 好中球機能抑制剤
KR20170052688A (ko) 알코올 홍조 및 알코올-유발성 과민 반응의 치료 및 예방을 위한 제제
EP2844277B1 (en) Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)
EP2686004B1 (en) Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
CN113975302A (zh) 一种降尿酸的广东虫草药酒及其制备方法与应用
CN108434160A (zh) N-乙酰-d-氨基葡萄糖盐在制备防治失眠药物及保健品中的应用及药物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160728

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 852967

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012026569

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170309

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2686006

Country of ref document: PT

Date of ref document: 20170320

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170313

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20161214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2618930

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170622

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170414

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170400613

Country of ref document: GR

Effective date: 20170804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 23759

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602012026569

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: KERNEBECK PATENTANWALTS GMBH

Effective date: 20170914

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033445

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170316

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

RIC2 Information provided on ipc code assigned after grant

Ipc: A61K 38/44 20060101AFI20190206BHEP

Ipc: A61K 31/522 20060101ALI20190206BHEP

Ipc: A61P 25/32 20060101ALI20190206BHEP

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 852967

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161214

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

REG Reference to a national code

Ref country code: CH

Ref legal event code: AELC

27A Patent maintained in amended form

Effective date: 20200219

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602012026569

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20200514

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: NO

Ref legal event code: TB2

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 23759

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200401329

Country of ref document: GR

Effective date: 20200716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161214

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2618930

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20201104

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230420

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240213

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240214

Year of fee payment: 13

Ref country code: IE

Payment date: 20240209

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240226

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240227

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240220

Year of fee payment: 13

Ref country code: DE

Payment date: 20240206

Year of fee payment: 13

Ref country code: CZ

Payment date: 20240228

Year of fee payment: 13

Ref country code: BG

Payment date: 20240220

Year of fee payment: 13

Ref country code: PT

Payment date: 20240315

Year of fee payment: 13

Ref country code: GB

Payment date: 20240208

Year of fee payment: 13

Ref country code: SK

Payment date: 20240213

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240212

Year of fee payment: 13

Ref country code: PL

Payment date: 20240214

Year of fee payment: 13

Ref country code: NO

Payment date: 20240222

Year of fee payment: 13

Ref country code: IT

Payment date: 20240212

Year of fee payment: 13

Ref country code: FR

Payment date: 20240213

Year of fee payment: 13

Ref country code: DK

Payment date: 20240314

Year of fee payment: 13

Ref country code: BE

Payment date: 20240216

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240408

Year of fee payment: 13